AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor (IL-36R) for the treatment of various dermatological inflammatory diseases; Rosnilimab, an anti-PD-1 agonist antibody program designed to augment PD-1 signaling through rosnilimab treatment to suppress T-cell driven human inflammatory diseases; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. and Bristol-Myers Squibb; and license agreements with United Kingdom Research and Innovation, as well as Millipore Corporation. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
Earnings for AnaptysBio, Inc. (ANAB)
Earnings in 2023 (TTM): $-163,623,000
According to AnaptysBio, Inc.'s latest financial reports the company's current earnings (TTM) are $-163,623,000. The earnings displayed on this page is the company's Pretax Income.
Earnings history of AnaptysBio, Inc.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-163,623,000 | $-163,619,000 |
| 2022 | $-128,700,000 | $-128,724,000 |
| 2021 | $-57,796,000 | $-57,193,000 |
| 2020 | $-19,931,000 | $-19,920,000 |
| 2019 | $-97,488,000 | $-97,336,000 |
| 2018 | $-61,848,000 | $-61,656,000 |
| 2017 | $-30,070,000 | $-30,070,000 |
| 2016 | $-4,259,000 | $-4,259,000 |
| 2015 | $-5,266,000 | $-5,405,000 |
| 2014 | $3.53 M | $3.53 M |
| 2013 | $-5,545,000 | $-5,545,000 |